Evening Brief: Hengrui Launches New Drug for Hyperuricemia, SIG Biotech’s Organoid+AI Gastric Cancer Therapy Receives FDA Fast Track Designation

1. Hengrui Launches New Drug, One-Third of the Coastal Population Saved

About 200 million people in China suffer from hyperuricemia, particularly young and middle-aged adults in coastal areas. Existing drugs have serious side effects, but the good news is that multiple new drugs will soon be launched in China. Pharmaceutical companies such as Hengrui Medicine will benefit.

2. The First "Organoid + AI" Gastric Cancer Innovative Drug Granted FDA Fast Track Designation, Overview of 48 Organoid Companies in China

SIGNET's Core Drug SIGX1094 Granted FDA Fast Track Designation; Developed Using "Organoid + AI" Technology for Treating Gastric Cancer, IND Approved with First Dosing Completed. Additionally, SIGNET Has Completed Multiple Rounds of Financing and Partnered with Yaosu Technology to Advance the Industrialization of Organoid Technology.

3. Meihua Holdings Group Launches 250 Million Employee Stock Ownership Plan, Synthetic Biology Mentioned Over 30 Times in Semi-Annual Report

Meihua Holdings Group Launches Employee Stock Ownership Plan with a Maximum Fundraising Limit of 2.5 Billion Yuan. As a Full-Chain Synthetic Biology Company, It Ranks Among the Global Leaders in Producing Amino Acids Through Synthetic Biological Technology and Owns Multiple Core Technologies and Intellectual Properties.

4. mRNA Vaccine Leader Faces Huge Losses Again, May Initiate Layoffs

Global mRNA Vaccine Giant Moderna Continues to Face Huge Losses in 2024, with a Net Loss of Approximately $3.6 Billion for the Year; Total Revenue Plummets from $6.8 Billion in 2023 to $3.2 Billion. The Company Predicts Further Revenue Decline for 2025, Estimated Between $1.5 and $2.5 Billion, Due to Increased Market Competition, Pricing Pressures, and Lower Vaccination Rates.

To address financial challenges, Moderna plans to cut approximately 50 employees from its digital team and further reduce costs by $1 billion in 2025. Although its COVID-19 business remains the primary revenue source, fourth-quarter revenue dropped 66% year-over-year. The newly launched RSV vaccine, mRESVIA, underperformed significantly below market expectations. Additionally, the FDA paused the Phase III study of the norovirus candidate vaccine due to a case of Guillain-Barré syndrome. Nevertheless, Moderna continues to pin its hopes on its R&D pipeline, aiming for up to 10 product approvals by 2027 and expecting key data from multiple vaccines in the coming years.

5. A Regenerative Medicine Company in China Completes Over 100 Million Yuan in Series B Financing

Seddicom Secures Over 100 Million Yuan in Series B Funding from H&L Partners and Shanghai Biomedical Fund for Core Product Commercialization and New Product R&D.

6. The "Returnee" of CXO

WuXi AppTec Shifts CGT Business Focus to China, Increases Investment in Shanghai WuXi ATU to 600 Million RMB to Mitigate Geopolitical Risks and Strengthen Strategic Position in CGT Sector Amid Surging Industry Demand. Previously Sold US and UK Operations.